Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Charite University, Berlin, Germany
With
Bayer
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Relapsing-remitting MS according to the revised McDonald-Criteria (2005)
EDSS ≤ 4.0
Stable treatment with Interferon-β1b for at least 6 months
Sufficient birth control (Pearl-Index \<1)
You may not be if
Any other MS-course than RRMS
Clinically relevant gastrointestinal disease
Clinically relevant pulmonary, cardiological, infectious or CNS-disease
Clinically relevant disease of liver or bile system, pathological value for transaminases, gamma-GT or bilirubin.
Hepatitis (except uncomplicated hepatitis A with complete remission
Clinically relevant dysfunction of kidneys (creatinine \>180 µmol/l) or bone marrow (HB \< 8.5 g/dl, WBC \< 2.5/nl thrombocytes \< 125/nl)
Myasthenia gravis
Oral anticoagulation (phenprocoumon)
Treatment with carbamazepine or paracetamol
Drug or alcohol abuse
Pregnancy or lactation period
Treatment at any time before or during study with complete lymphoradiation, monoclonal antibodies (e.g. anti-CD4, Campath 1H, natalizumab), mitoxantrone, cyclophosphamide, cyclosporin, azathioprine
Treatment within 6 months before randomization with any other immunomodulatory substance than interferon-β1b or intravenous methylprednisolone
Clareo Health | Flupirtine as Oral Treatment in Multiple Sclerosis
